Pelareorep is an oncolytic RV which had shown preclinical efficacy in immunocompetent glioma models after intravenous injection when combined with preconditioning with granulocyte-macrophage colony-stimulating factor (GM-CSF), which recruits APCs to the TIME [62]. This evidence concerns the gene CSF2 and central nervous system cancer.